Gliadel Marketing For Newly-Diagnosed Glioma Will Highlight Survival Benefit
Executive Summary
Guilford's marketing of Gliadel for use in patients undergoing surgery for newly-diagnosed malignant glioma will highlight the survival benefit, the company said after receiving the supplemental indication
You may also be interested in...
Avastin Clinical Benefit Trumps Anti-Tumor Effect In Glioblastoma, ODAC Says
Demonstration of an anti-tumor effect is not essential for a brain cancer indication if clinical benefit is provided, FDA's Oncology Drugs Advisory Committee indicated March 31 in recommending accelerated approval of Genentech's Avastin to treat relapsed glioblastoma multiforme
Avastin Clinical Benefit Trumps Anti-Tumor Effect In Glioblastoma, ODAC Says
Demonstration of an anti-tumor effect is not essential for a brain cancer indication if clinical benefit is provided, FDA's Oncology Drugs Advisory Committee indicated March 31 in recommending accelerated approval of Genentech's Avastin to treat relapsed glioblastoma multiforme
Avastin sBLA Clears Advisory Committee, Faces Quality of Life Hurdle
Accelerated approval for glioblastoma multiforme can be based on objective response rate, panel tells FDA.